These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34498503)

  • 1. Progressive vitreous deposits during treatment with inotersen for hereditary ATTR amyloidosis.
    Marques JH; Coelho J; Menéres MJ; Beirão JM
    Amyloid; 2021 Dec; 28(4):275-276. PubMed ID: 34498503
    [No Abstract]   [Full Text] [Related]  

  • 2. Inotersen treatment for ATTR amyloidosis.
    Benson MD
    Amyloid; 2019; 26(sup1):27-28. PubMed ID: 31343345
    [No Abstract]   [Full Text] [Related]  

  • 3. Neurofilament light chain as a biomarker for monitoring response to change in treatment in hereditary ATTR amyloidosis.
    Sato M; Mochizuki Y; Takahashi Y; Takasone K; Aldinc E; Ticau S; Jia G; Sekijima Y
    Amyloid; 2023 Sep; 30(3):351-352. PubMed ID: 36908191
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of ATTR cardiomyopathy with a TTR specific antisense oligonucleotide, inotersen.
    Dasgupta NR; Benson MD
    Amyloid; 2019; 26(sup1):20-21. PubMed ID: 31343363
    [No Abstract]   [Full Text] [Related]  

  • 5. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.
    Gertz MA; Scheinberg M; Waddington-Cruz M; Heitner SB; Karam C; Drachman B; Khella S; Whelan C; Obici L
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):701-711. PubMed ID: 31268366
    [No Abstract]   [Full Text] [Related]  

  • 6. Myelopathy in hereditary ATTR Val30Met amyloidosis patients.
    Videira G; Pereira D; Mota Dória H; Sousa AP; Coelho T; Martins da Silva A
    Amyloid; 2021 Dec; 28(4):271-272. PubMed ID: 33988057
    [No Abstract]   [Full Text] [Related]  

  • 7. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing Therapy for Transthyretin Amyloidosis.
    Campbell CM; Zhang K; Lenihan DJ; Witteles R
    Am J Med; 2022 Apr; 135 Suppl 1():S44-S48. PubMed ID: 35077703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytodiagnosis and protein typing of amyloid from a vitreous washing: initial diagnostic workup of hereditary amyloidosis.
    Coppock JD; Dusenbery AC; Elghawy O; Fellenstein LA; Frierson HF; Shildkrot Y
    J Am Soc Cytopathol; 2020; 9(3):173-176. PubMed ID: 32113804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hereditary ATTR amyloidosis: a single-institution experience with 266 patients.
    Swiecicki PL; Zhen DB; Mauermann ML; Kyle RA; Zeldenrust SR; Grogan M; Dispenzieri A; Gertz MA
    Amyloid; 2015; 22(2):123-31. PubMed ID: 26017327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TTR Gene Silencers for Hereditary ATTR Amyloidosis: More than ICER Recognized.
    Berk JL
    J Manag Care Spec Pharm; 2019 Jan; 25(1):15-16. PubMed ID: 30589634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early diagnosis and management of patients with familial ATTR amyloidosis receiving livers from asymptomatic variant TTR carriers.
    Munar-Qués M; Viader-Farré C; Zabay-Becerril JM; Mulet-Ferrer JM
    Amyloid; 2011 Sep; 18(3):172-3. PubMed ID: 21774739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful use of palliative inotrope therapy in end-stage cardiac ATTR amyloidosis.
    Panhwar MS; Al-Kindi S; Oliveira GH; Ginwalla M
    Amyloid; 2017 Dec; 24(4):217-218. PubMed ID: 28868918
    [No Abstract]   [Full Text] [Related]  

  • 14. Factors associated with increased health-related quality-of-life benefits in hereditary transthyretin amyloidosis polyneuropathy patients treated with inotersen.
    Karam C; Brown D; Yang M; Done N; Dieye I; Bozas A; Vera Llonch M; Signorovitch J
    Muscle Nerve; 2022 Sep; 66(3):319-328. PubMed ID: 35766224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the treatment of hereditary transthyretin amyloidosis: A review.
    Gertz MA; Mauermann ML; Grogan M; Coelho T
    Brain Behav; 2019 Sep; 9(9):e01371. PubMed ID: 31368669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis.
    Benson MD; Dasgupta NR; Monia BP
    Neurodegener Dis Manag; 2019 Feb; 9(1):25-30. PubMed ID: 30561247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial.
    Brannagan TH; Wang AK; Coelho T; Waddington Cruz M; Polydefkis MJ; Dyck PJ; Plante-Bordeneuve V; Berk JL; Barroso F; Merlini G; Conceição I; Hughes SG; Kwoh J; Jung SW; Guthrie S; Pollock M; Benson MD; Gertz M;
    Eur J Neurol; 2020 Aug; 27(8):1374-1381. PubMed ID: 32343462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis.
    Brown EE; Lee YZJ; Halushka MK; Steenbergen C; Johnson NM; Almansa J; Tedford RJ; Cingolani O; Russell SD; Sharma K; Judge DP
    Amyloid; 2017 Jun; 24(2):92-95. PubMed ID: 28494620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inotersen for the Treatment of Hereditary Transthyretin Amyloidosis.
    Mahfouz M; Maruyama R; Yokota T
    Methods Mol Biol; 2020; 2176():87-98. PubMed ID: 32865784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Origin of sporadic late-onset hereditary ATTR Val30Met amyloidosis in Japan.
    Ueda M; Yamashita T; Misumi Y; Masuda T; Ando Y
    Amyloid; 2018 Sep; 25(3):143-147. PubMed ID: 30486687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.